Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Pharmacokinetic Investigation of Commercially Available Edible Marijuana Products in Humans: Potential Influence of Body Composition and Influence on Glucose Control

Version 1 : Received: 15 July 2021 / Approved: 16 July 2021 / Online: 16 July 2021 (09:24:11 CEST)

How to cite: Ewell, T.R.; Abbotts, K.S.S.; Williams, N.N.B.; Butterklee, H.M.; Bomar, M.C.; Harms, K.J.; Rebik, J.D.; Mast, S.M.; Akagi, N.; Dooley, G.P.; Bell, C. Pharmacokinetic Investigation of Commercially Available Edible Marijuana Products in Humans: Potential Influence of Body Composition and Influence on Glucose Control. Preprints 2021, 2021070365 (doi: 10.20944/preprints202107.0365.v1). Ewell, T.R.; Abbotts, K.S.S.; Williams, N.N.B.; Butterklee, H.M.; Bomar, M.C.; Harms, K.J.; Rebik, J.D.; Mast, S.M.; Akagi, N.; Dooley, G.P.; Bell, C. Pharmacokinetic Investigation of Commercially Available Edible Marijuana Products in Humans: Potential Influence of Body Composition and Influence on Glucose Control. Preprints 2021, 2021070365 (doi: 10.20944/preprints202107.0365.v1).

Abstract

The purpose of the study was to describe and compare the pharmacokinetics of five commercial edible marijuana products, determine the influence of body composition on pharmacokinetics, and, in light of epidemiology suggesting marijuana may offer diabetes protection, explore the influence of edible marijuana on glucose tolerance. Seven regular users of marijuana self-administered five edible products in a randomized crossover design; each product contained 10mg of delta-9-tetrahydrocannabinol (THC). 30-minutes following marijuana ingestion, participants imbibed a 75g glucose beverage. Time-to-peak plasma THC concentration ranged between 35 and 90 minutes; maximal plasma THC concentration (Cmax) ranged between 3.2 and 5.5 ng/mL. Differences between products in plasma THC concentration during the first 20-to-30 minutes were detected (P=0.019). Relations were identified between body composition and pharmacokinetic parameters for some products; however, none of these body composition characteristics were consistently related to pharmacokinetics across all five of the products. Edible marijuana had no effect on oral glucose tolerance compared with a marijuana-free control (Matsuda Index; P>0.395). Commercially available edible marijuana products evoke different plasma THC concentrations shortly after ingestion, but do not appear to influence acute glucose regulation. These data may allow marijuana users to make informed decisions pertaining to rates of edible marijuana ingestion and avoid overdose.

Keywords

cannabis; cannabinoid; diabetes; insulin

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.